Major, Tanya J.
Dalbeth, Nicola
Stahl, Eli A.
Merriman, Tony R.
Article History
First Online: 8 May 2018
Competing interests
: N.D. declares that she has received consulting fees, speaker fees or grants from Ardea/AstraZeneca, Cymabay, Crealta, Horizon and Takeda, which have developed or marketed urate-lowering therapies for management of gout. T.R.M. declares that he has received consulting fees, speaker fees or grants from Ardea/AstraZeneca and Horizon, which have developed or marketed urate-lowering therapies for management of gout. The other authors declare no competing interests.